Investment Rating - The report initiates coverage on Samsung Medical with a "Buy" rating and a target price of RMB 30.00 [1][4][5]. Core Insights - The company is a leading domestic manufacturer of medium and low voltage electrical equipment, primarily producing distribution transformers and smart meters. Despite a 25% decline in stock price year-to-date, the report anticipates a recovery in smart meter demand starting in 2026 due to a new replacement cycle. Additionally, strong overseas demand for distribution transformers may mitigate cyclical risks [1][12][45]. - The report projects a 27% CAGR for EPS from 2025 to 2027, with a 16% growth rate expected in 2025. The current stock price corresponds to a 9x PE for 2026E, below the historical average of 13.4x. The company maintains a stable dividend payout ratio of 55%, with expected dividend yields of 5-6% for 2025-2026 [1][4][12]. Summary by Sections Smart Meter Concerns - The report acknowledges concerns regarding smart meter demand in 2024 due to high base effects but expects a rebound in 2026. Historical data indicates that new standards typically lead to a drop in demand in the year of implementation, followed by growth in subsequent years. The company is also positioned to benefit from increasing market share in overseas smart meter and distribution transformer markets [2][13][16]. Medical Services Profitability - Approximately 20% of the company's revenue comes from rehabilitation hospitals. The average length of hospital stays in tertiary hospitals has decreased significantly, indicating a rising demand for rehabilitation services. The company’s bed occupancy rate is below the national average, suggesting potential for improvement in profitability [3][31]. Valuation - The report employs a Sum-of-the-Parts (SOTP) valuation method, arriving at a 12-month target price of RMB 30.00. The power equipment segment is valued at 11.5x forward PE, while the healthcare services segment is valued at 18x, aligning with industry averages. The target price implies a 12.4x PE for 2026E, with an expected EPS CAGR of 23% from 2024 to 2027 [4][46]. Revenue Growth Projections - The report forecasts a 26% CAGR for power equipment revenue from 2024 to 2027, driven by strong growth in distribution equipment (38% CAGR) and smart meters (8% CAGR). The overall revenue growth for the power equipment segment is expected to be supported by a 26% increase in orders [8][23][24]. Dividend and Cash Position - The company is in a net cash position, which supports its ability to pay dividends. The report anticipates a stable dividend payout ratio of at least 45% from 2025 to 2027, with an average payout ratio of 54% from 2020 to 2024 [38][41].

Core Viewpoint - Samsung Medical's stock closed at 21.71 yuan, down 1.99%, with a rolling PE ratio of 12.85 times, significantly lower than the industry average of 35.02 times [1][2] Company Overview - Samsung Medical's main business segments include smart power distribution and medical services, with key products such as smart meters, high-end gateway meters, and various energy solutions [1] - The company has received multiple accolades, including being recognized as a national-level intellectual property demonstration enterprise and a provincial key enterprise research institute [1] Financial Performance - For Q1 2025, Samsung Medical reported revenue of 36.31 billion yuan, a year-on-year increase of 20.03%, and a net profit of 4.89 billion yuan, up 34.33% [2] - The company's gross profit margin stands at 28.90% [2] Market Position - Samsung Medical ranks 36th in the electric grid equipment industry based on PE ratio, with a total market capitalization of 306.33 billion yuan [1][2] - The company is held by 101 institutions, including 99 funds, with a total shareholding of 61,407.10 million shares valued at 181.58 billion yuan [1]

Group 1 - Chengjian Development received a dividend of 7.1282 million yuan from Beijing Jingcheng Jiaye Property Co., Ltd., in which it holds a 33.47% stake [1] - Shengnuo Bio expects a net profit attributable to shareholders of 77.0275 million to 94.1448 million yuan for the first half of 2025, representing a year-on-year increase of 253.54% to 332.10% [1] - JKN2301 dry mixed suspension has been approved for clinical trials, targeting children with influenza [5][6] Group 2 - Jindawei obtained a patent for a method of purifying natto kinase, with a validity of twenty years [2] - CITIC Guoan plans to increase its stake in China Broadcasting Hunan Company to approximately 5.29% through a capital increase of 278 million yuan [2] - Ji Electric announced the resignation of its general manager, Niu Guojun, due to work changes [3] Group 3 - Xintian Green Energy successfully issued 1.5 billion yuan in green medium-term notes with a term of 3+N years and an interest rate of 2.05% [7] - Hengrun Co. plans to invest 1.2 billion yuan in a project to produce 2,000 sets of wind turbine gearbox components [9] - Pulaide received a government subsidy of 10 million yuan, accounting for 15.87% of its audited net profit for the last fiscal year [10] Group 4 - Boteng Co. passed the EU QP audit, receiving a compliance statement for its CDMO services [12] - Zhou Dasheng added 7 self-operated stores in May, with total investments ranging from 900,000 to 6.5 million yuan [13] - Wantai Bio initiated a Phase III clinical trial for its live attenuated varicella vaccine [15] Group 5 - Shanghai Pharmaceuticals received a drug registration certificate for Pregabalin capsules in Thailand [19] - Sanxing Medical's subsidiary is expected to win contracts worth approximately 143 million yuan from State Grid projects [21] - Jiangsu Huachen plans to issue 460 million yuan in convertible bonds [24] Group 6 - Jian Gong Repair won a soil pollution remediation project worth 32.76 million yuan [25] - Dize Pharmaceutical completed patient enrollment for a global Phase III clinical trial of its drug [26] - Del Co. received acceptance for its application to issue shares for asset acquisition and raise matching funds [27] Group 7 - Beijing Kerui won multiple power grid projects with a total value of approximately 154 million yuan [27] - Xie Chuang Data signed financing lease contracts totaling 498 million yuan with Su Yin Financial Leasing [28] - Meige Intelligent submitted an application for H-share listing on the Hong Kong Stock Exchange [29][31] Group 8 - Aikodi plans to repurchase shares worth 100 million to 200 million yuan for employee stock ownership plans [54] - Kong Kong Industrial intends to sell 80% of Tianyuan Construction to its controlling shareholder [55] - Youyou Green Energy proposed a cash dividend of 12 yuan per 10 shares, totaling 50.4 million yuan [55]

宁波三星医疗电气股份有限公司（以下简称"公司"）下属全资子公司宁波奥克斯 智能科技股份有限公司（以下简称"奥克斯智能科技"）于近日在国家电网有限公司 2025 年华东区域第一次联合采购 10kV 变压器协议库存招标采购项目、2025 年华东区 域第一次联合采购 10kV 柱上变压器台成套设备协议库存招标采购项目中被推荐为中 标候选人，预计合计中标总金额约为 14,338.07 万元，现将预中标情况公告如下： 一、国家电网项目预中标的主要内容 1、10kV变压器协议库存招标采购项目 证券代码：601567 证券简称：三星医疗 公告编号：临 2025-049 宁波三星医疗电气股份有限公司 关于经营合同预中标的提示性公告 本公司董事会及全体董事保证公告内容不存在虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据公示内容，公司为此项目10kV非晶合金变压器、10kV硅钢片油浸变压器、 10kV干式变压器的中标候选人，根据公司预中标数量及报价测算，预计中标总金额约 为12,324.55万元。 二、预中标项目对公司业绩的影响 本次公司预中标金额约为14,338.07万元，交货时间需 ...

Group 1 - The high-pressure oxygen chamber concept declined by 2.26%, ranking among the top declines in concept sectors, with companies like Aoyang Health, International Medicine, and Weiao Co., Ltd. experiencing significant drops [1] - The main funds in the high-pressure oxygen chamber concept saw a net outflow of 363 million yuan, with seven stocks experiencing net outflows, led by Innovation Medical with a net outflow of 308 million yuan [2] - Other companies with notable net outflows include Aoyang Health, Dahu Co., Ltd., and Yinkang Life, with net outflows of 27.01 million yuan, 8.53 million yuan, and 6.79 million yuan respectively [2] Group 2 - The top gainers in concept sectors included the military equipment restructuring concept, which rose by 3.51%, and PCB concept, which increased by 3.29% [2] - The high-pressure oxygen chamber concept was among the sectors with the largest declines, alongside glyphosate and rare earth permanent magnets, which fell by 2.82% and 2.57% respectively [2] - The trading volume for the high-pressure oxygen chamber concept stocks showed varying turnover rates, with Innovation Medical at 36.76% and Aoyang Health at 17.53% [2]

Core Points - Samsung Medical's stock closed at 22.34 yuan on June 13, 2025, down 0.18% from the previous week [1] - The company's market capitalization is currently 31.522 billion yuan, ranking 8th out of 120 in the power equipment sector and 454th out of 5,150 in the A-share market [1] Company Announcements - Samsung Medical announced a change in the purpose of repurchased shares, converting 5,755,371 shares for cancellation and reduction of registered capital, resulting in a new total share count of 1,405,251,200 shares [1] - The company held its 2025 first extraordinary general meeting, where the resolution to change the purpose of repurchased shares was approved with 99.9127% of votes in favor [2] - The company notified creditors of their rights to claim debts or request guarantees within specified timeframes following the announcement [1]

证券代码：601567 证券简称：三星医疗 公告编号：临2025-047 宁波三星医疗电气股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 本次会议是否有否决议案：无 二、 议案审议情况 (二)股东会召开的地点：宁波市鄞州区首南街道日丽中路 757 号奥克斯中央大厦 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： 份总数的比例（%） 50.5697 注：上表中公司有表决权股份总数不含公司回购账户中的股份数，本次已剔除。 (四)表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况等。 本次股东会由公司董事会召集，董事长沈国英女士主持，采用现场投票和网 络投票相结合的表决方式。会议召开符合《公司法》和《公司章程》的有关规定。 (五)公司董事、监事和董事会秘书的出席情况 股东会。 一、 会议召开和出席情况 (一)股东会召开的时间：2025 年 6 月 13 日 (一)非累积投票议案 审议结果：通过 表决情况： | 股东类型 | 同意 | | | 反对 | | 弃权 | ...

Group 1 - The company has decided to change the purpose of 5,755,371 repurchased shares from employee stock ownership plans to cancellation and reduction of registered capital, aiming to optimize shareholder returns and enhance investor confidence [1][2] - Following the cancellation, the total share capital is expected to decrease from 1,411,006,571 shares to 1,405,251,200 shares, and the registered capital will reduce from 1,411,006,571 yuan to 1,405,251,200 yuan [2] - The company is notifying creditors that they have 30 days from receiving the notice, or 45 days from the announcement date if not notified, to claim their debts or request guarantees [2][3] Group 2 - Creditors must provide valid documentation to prove their claims, including contracts and agreements, and must follow specific procedures for debt declaration [3] - The company has outlined the office hours for creditors to submit their claims, which are from 8:30 AM to 12:00 PM and 1:30 PM to 6:00 PM on weekdays [3]

重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东会召开的时间：2025 年 6 月 13 日 (二)股东会召开的地点：宁波市鄞州区首南街道日丽中路 757 号奥克斯中央大厦 25 楼会议室 证券代码：601567 证券简称：三星医疗 公告编号：临2025-047 宁波三星医疗电气股份有限公司 2025年第一次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 审议结果：通过 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 925 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 707,721,246 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 50.5697 | 注：上表中公司有表决权股份总数不含公司回购账户中的股份数，本次已剔除。 (四)表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况等。 本次股东会由公司董事 ...

证券代码：601567 证券简称：三星医疗 公告编号：临 2025-048 宁波三星医疗电气股份有限公司 关于注销部分回购股份减少注册资本通知债权人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、通知债权人的原由 宁波三星医疗电气股份有限公司（以下简称"公司"）于 2025 年 5 月 28 日召 开第六届董事会第二十三次会议，审议通过了《关于变更部分回购股份用途为注 销并减少公司注册资本的议案》。基于对公司未来发展的信心和对公司长期价值 的认同，为切实优化股东投资回报，增强投资者的投资信心，公司拟将存放于股 份回购专用证券账户中已回购尚未使用的 5,755,371 股股份用途进行变更，由"用 于实施员工持股计划或股权激励计划"变更为"用于注销并减少公司注册资本"。 该事项已经公司于 2025 年 6 月 13 日召开的 2025 年第一次临时股东会审议通过。 详见 2025 年 5 月 29 日、2025 年 6 月 14 日刊登于上海证券交易所网站 （http://www.sse.com.cn）及《上海证券报》 ...